Table 1.
Demographic, clinical and biological profile of patients with HIV started on antiretroviral therapy at the Yaounde Jamot Hospital in 2007 and 2008
| Characteristics* | Overall | Men | Women | p Value |
|---|---|---|---|---|
| N | 1444 | 617 | 827 | |
| Median age, years (25–75th centile) | 38 (31–45) | 40 (34–47) | 35 (30–43) | <0.0001 |
| Residence, n (%) | 0.98 | |||
| Urban | 1236 (85.6) | 528 (85.6) | 708 (85.6) | |
| Rural | 208 (14.4) | 89 (14.4) | 119 (14.4) | |
| Tuberculosis | 428 (29.6) | 214 (34.7) | 214 (27.9) | 0.0003 |
| Weight (kg), n (%) | <0.0001 | |||
| <50 | 308/1322 (23.3) | 69/570 (12.1) | 239/752 (31.8) | |
| 50–60 | 535/1322 (40.5) | 204/570 (35.8) | 331/752 (44.0) | |
| >60, n | 479/1322 (36.2) | 297/570 (52.1) | 182/752 (24.2) | |
| Median (25–75th centile) | 57 (50–65) | 61 (54–68) | 54 (47.5–60) | <0.0001 |
| WHO stage, n (%) | 0.82 | |||
| I and II | 186/1295 (14.4) | 78/553 (14.1) | 108/742 (14.6) | |
| III and IV | 1109/1295 (85.6) | 475/553 (85.9) | 634/742 (85.4) | |
| Platelets, ×1000/mm3 | 244 (180–320) | 229 (173–309) | 259 (190–330) | 0.0005 |
| Total lymphocytes, ×10/mm3 | 130 (90–190) | 130 (90–201) | 130 (90–190) | 0.88 |
| CD4 (/mm3), n (%) | 0.21 | |||
| <50 | 468 (32.4) | 216 (30.5) | 256 (30.5) | |
| 50–99 | 257 (17.8) | 111 (18.0) | 142 (17.6) | |
| 100–200 | 562 (38.9) | 231 (37.4) | 331 (40.0) | |
| >200 | 157 (10.9) | 59 (9.6) | 98 (11.8) | |
| Median (25–75th centile) | 99 (36.2–161) | 89 (33–155) | 105 (39–166) | 0.02 |
| Haemoglobin (g/dL), n (%) | <0.0001 | |||
| <8 | 235/1388 (16.9) | 67/594 (11.3) | 168/794 (21.2) | |
| 8–10 | 506/1388 (36.5) | 178/594 (30.0) | 328/794 (41.3) | |
| >10 | 647/1388 (46.6) | 349 (58.7) | 298 (37.5) | |
| Median (25–75th centile) | 9.9 (8.5–11.2) | 10.5 (9–12) | 9.5 (8.1–10.7) | <0.0001 |
*For all characteristics with missing values, estimates are based on the subset of participants with valid data for each relevant characteristic, and new denominators always provided.
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.